CO2024012622A2 - Anticuerpos capaces de unirse a la proteína de la espícula de coronavirus sars-cov-2 - Google Patents
Anticuerpos capaces de unirse a la proteína de la espícula de coronavirus sars-cov-2Info
- Publication number
- CO2024012622A2 CO2024012622A2 CONC2024/0012622A CO2024012622A CO2024012622A2 CO 2024012622 A2 CO2024012622 A2 CO 2024012622A2 CO 2024012622 A CO2024012622 A CO 2024012622A CO 2024012622 A2 CO2024012622 A2 CO 2024012622A2
- Authority
- CO
- Colombia
- Prior art keywords
- cov
- binding
- spike protein
- antibodies capable
- coronavirus sars
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/102—Coronaviridae (F)
- C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2202232.1A GB202202232D0 (en) | 2022-02-18 | 2022-02-18 | Antibodies |
| GBGB2203423.5A GB202203423D0 (en) | 2022-03-11 | 2022-03-11 | Antibodies |
| GB202206777 | 2022-05-09 | ||
| GBGB2212470.5A GB202212470D0 (en) | 2022-08-26 | 2022-08-26 | Antibodies |
| GBGB2214036.2A GB202214036D0 (en) | 2022-09-26 | 2022-09-26 | Antibodies |
| GBGB2215418.1A GB202215418D0 (en) | 2022-10-18 | 2022-10-18 | Antibodies |
| GBGB2301959.9A GB202301959D0 (en) | 2023-02-10 | 2023-02-10 | Antibodies |
| PCT/EP2023/054109 WO2023156636A1 (en) | 2022-02-18 | 2023-02-17 | Antibodies capable of binding to the spike protein of coronavirus sars-cov-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024012622A2 true CO2024012622A2 (es) | 2024-12-30 |
Family
ID=86497315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0012622A CO2024012622A2 (es) | 2022-02-18 | 2024-09-17 | Anticuerpos capaces de unirse a la proteína de la espícula de coronavirus sars-cov-2 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250154231A1 (https=) |
| EP (1) | EP4479425A1 (https=) |
| JP (1) | JP2025507595A (https=) |
| KR (1) | KR20240142594A (https=) |
| CN (1) | CN119403828B (https=) |
| AU (1) | AU2023220851A1 (https=) |
| CA (1) | CA3252608A1 (https=) |
| CO (1) | CO2024012622A2 (https=) |
| CR (1) | CR20240389A (https=) |
| GB (1) | GB2614651B (https=) |
| IL (1) | IL315020A (https=) |
| MX (1) | MX2024010178A (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250289871A1 (en) | 2022-04-29 | 2025-09-18 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
| GB202316016D0 (en) * | 2023-10-19 | 2023-12-06 | Univ Oxford Innovation Ltd | Antibodies |
| CN121471347B (zh) * | 2026-01-12 | 2026-03-27 | 中国人民解放军军事科学院军事医学研究院 | 一种抗SARS-CoV和SARS-CoV-2的全人源单克隆抗体及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250107297A (ko) * | 2020-04-02 | 2025-07-11 | 리제너론 파아마슈티컬스, 인크. | 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편 |
| MX2021015024A (es) * | 2020-04-28 | 2022-01-18 | Univ Rockefeller | Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos. |
| WO2021231237A2 (en) * | 2020-05-11 | 2021-11-18 | Augmenta Bioworks, Inc. | Antibodies for sars-cov-2 and uses thereof |
| WO2021229561A1 (en) * | 2020-05-14 | 2021-11-18 | The Israel Institute of Biological Research (IIBR) | Anti-sars-cov-2 antibodies |
-
2023
- 2023-02-17 JP JP2024548670A patent/JP2025507595A/ja active Pending
- 2023-02-17 EP EP23707291.3A patent/EP4479425A1/en active Pending
- 2023-02-17 CR CR20240389A patent/CR20240389A/es unknown
- 2023-02-17 CA CA3252608A patent/CA3252608A1/en active Pending
- 2023-02-17 GB GB2305426.5A patent/GB2614651B/en active Active
- 2023-02-17 AU AU2023220851A patent/AU2023220851A1/en active Pending
- 2023-02-17 IL IL315020A patent/IL315020A/en unknown
- 2023-02-17 CN CN202380034355.XA patent/CN119403828B/zh active Active
- 2023-02-17 US US18/839,067 patent/US20250154231A1/en active Pending
- 2023-02-17 KR KR1020247030884A patent/KR20240142594A/ko active Pending
-
2024
- 2024-08-19 MX MX2024010178A patent/MX2024010178A/es unknown
- 2024-09-17 CO CONC2024/0012622A patent/CO2024012622A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240142594A (ko) | 2024-09-30 |
| MX2024010178A (es) | 2024-12-06 |
| GB2614651A (en) | 2023-07-12 |
| CR20240389A (es) | 2025-05-05 |
| CA3252608A1 (en) | 2023-08-24 |
| GB2614651B (en) | 2024-03-06 |
| US20250154231A1 (en) | 2025-05-15 |
| IL315020A (en) | 2024-10-01 |
| AU2023220851A1 (en) | 2024-09-26 |
| EP4479425A1 (en) | 2024-12-25 |
| JP2025507595A (ja) | 2025-03-21 |
| GB202305426D0 (en) | 2023-05-31 |
| CN119403828A (zh) | 2025-02-07 |
| CN119403828B (zh) | 2025-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024012622A2 (es) | Anticuerpos capaces de unirse a la proteína de la espícula de coronavirus sars-cov-2 | |
| CL2024002462A1 (es) | Anticuerpos capaces de unirse a la proteína de la espícula de coronavirus sars-cov-2 | |
| CO2020009625A2 (es) | Inhibidor de fap | |
| MX2021002322A (es) | Nuevos metodos. | |
| AR121361A1 (es) | Vacuna | |
| CO6680687A2 (es) | Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas | |
| WO2022167816A3 (en) | Antibodies | |
| AR061171A1 (es) | Proteinas de union al factor de crecimiento de hepatocitos (fch) | |
| AR061170A1 (es) | Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf) | |
| MX2022013453A (es) | Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas. | |
| ECSP23025065A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| CR11837A (es) | Inmunoglobulinas con dominio variable dual y usos de la misma | |
| CR20120154A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| BR112022022456A2 (pt) | Proteínas de ligação de repetição de anquirina e seus usos | |
| CR20120266A (es) | Inmunoglobinas con dominio variable dual y usos de las mismas | |
| CR20240363A (es) | Compuestos y métodos para el tratamiento de infecciones virales. | |
| ECSP21031200A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| BR112022027101A2 (pt) | Anticorpos multiespecíficos que se ligam a bcma | |
| AR122380A1 (es) | Uso de inhibidores de sglt-2 para la prevención y/o tratamiento de enfermedades cardíacas en felinos | |
| MX394623B (es) | Tecnología de sinergismo anticuerpo-fármaco para el tratamiento de enfermedades. | |
| MX2020010932A (es) | Enzimas quinureninasa humanas y sus usos. | |
| ECSP077220A (es) | Tratamiento de infecciones bacterianas | |
| BR112021018611A2 (pt) | Anticorpos tendo especificidade para btn2 e usos dos mesmos | |
| MX2023001238A (es) | Proteina de union a antigeno. | |
| AR053775A1 (es) | Nonadepsipeptidos acilados ii |